<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-147813" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tirzepatide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-147813.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tirzepatide is a novel medication approved by the US Food and Drug Administration (FDA) for treating&#x000a0;type 2 diabetes mellitus (T2DM). This medication also&#x000a0;demonstrates efficacy in weight loss, leading to its off-label use for obesity treatment.&#x000a0;Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The drug leads to significantly improved glycemic control and weight reduction in patients with T2DM, maximizing benefits similar to GLP-1 medications such as semaglutide.</p>
        <p>Tirzepatide is currently utilized as a second-line diabetes medication akin to GLP-1 drugs, such as semaglutide, and is administered once weekly via subcutaneous injection with incremental dosage adjustments.&#x000a0;Tirzepatide is not approved for the treatment of type 1 diabetes mellitus (T1DM) and has not undergone studies in patients with pancreatitis. The most commonly reported adverse effects of the drug are gastrointestinal, including nausea, vomiting, and diarrhea.&#x000a0;This activity provides an overview of the indications, mechanism of action, adverse effects, contraindications, and important considerations for using tirzepatide. This activity also aids clinicians in gaining proficiency in administering tirzepatide and managing&#x000a0;T2DM in patients, thereby enhancing overall outcomes in patient care and safety.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for tirzepatide therapy based on their clinical profile and treatment goals.</p></list-item><list-item><p>Assess patient response to tirzepatide therapy by regularly monitoring glycemic control and weight changes.</p></list-item><list-item><p>Select optimal combination therapies or alternative treatment options for patients with complex medical histories or treatment-resistant diabetes.</p></list-item><list-item><p>Collaborate with interdisciplinary healthcare teams to coordinate&#x000a0;care transitions and follow-up appointments to facilitate continuity of tirzepatide therapy and monitor long-term outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=147813&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=147813">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-147813.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Tirzepatide is a novel medication approved by the US Food and Drug Administration (FDA) in May 2022 for treating&#x000a0;type 2 diabetes mellitus (T2DM).&#x000a0;Tirzepatide is a synthetic polypeptide and dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.&#x000a0;Therefore, the drug leads to significantly improved glycemic control and weight reduction in patients with T2DM, maximizing benefits similar to GLP-1 medications such as semaglutide.<xref ref-type="bibr" rid="article-147813.r1">[1]</xref></p>
        <p>Tirzepatide is currently utilized as a second-line diabetes medication akin to GLP-1 drugs, such as semaglutide, and is administered once weekly via subcutaneous (SQ) injection with incremental dosage adjustments.<xref ref-type="bibr" rid="article-147813.r2">[2]</xref></p>
        <p>Current clinical data demonstrated that tirzepatide is superior to placebo in improving hemoglobin A1c (HbA1c) levels. The SURPASS-5 clinical trial showed a -2.11% reduction in HbA1c levels at 5 mg per week dosing, compared to -0.86% with a placebo. At the highest dose of 15 mg per week, tirzepatide led to a -2.34% reduction in HbA1c. This was demonstrated over 40 weeks. A weight reduction of 5.4 kg was seen with 5 mg of tirzepatide dosing, and a 10.5 kg reduction was&#x000a0;observed with 15 mg dosing. This dose-dependent correlation with weight loss is similar to semaglutide&#x02014;a common GLP-1 medication utilized for weight loss management.<xref ref-type="bibr" rid="article-147813.r3">[3]</xref></p>
        <p>The results of the SURPASS trials demonstrate that tirzepatide yields clinically&#x000a0;significant improvements in glycemic control and weight loss when compared with other GLP-1 receptor agonists (semaglutide and dulaglutide), insulin degludec, and insulin glargine. Consequently, the American Diabetes Association (ADA) categorizes tirzepatide as a highly effective therapy for achieving glycemic control and weight loss.<xref ref-type="bibr" rid="article-147813.r4">[4]</xref><xref ref-type="bibr" rid="article-147813.r5">[5]</xref></p>
        <p>Comparatively, tirzepatide works&#x000a0;similarly to GLP-1 medications but with greater efficacy. Given&#x000a0;the weight loss properties and lack of liver toxicity,<xref ref-type="bibr" rid="article-147813.r6">[6]</xref>&#x000a0;it is likely to have an indirect role in the treatment of nonalcoholic fatty liver disease. However, further research is needed before&#x000a0;the use is approved for metabolic dysfunction-associated steatotic liver disease.<xref ref-type="bibr" rid="article-147813.r7">[7]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Tirzepatide is not approved for the treatment of type 1 diabetes mellitus (T1DM) and has not undergone studies in patients with pancreatitis. Tirzepatide can also&#x000a0;demonstrate efficacy in weight loss, leading to its off-label use for obesity treatment.</p>
      </sec>
      <sec id="article-147813.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Tirzepatide is a synthetic polypeptide dual agonist for GLP-1 and GIP. Tirzepatide, "twincretin," exhibits distinct characteristics from GLP-1 receptor agonists.<xref ref-type="bibr" rid="article-147813.r8">[8]</xref>&#x000a0;The medication comprises 39 amino acids and is an analog of the gastric inhibitory polypeptide. Functionally,&#x000a0;tirzepatide&#x000a0;stimulates insulin release from the pancreas and reduces hyperglycemia. In addition, tirzepatide also increases the levels of adiponectin.&#x000a0;</p>
        <p>The dual agonism ability decreases hyperglycemia significantly more than GLP-1 agonist agents and&#x000a0;reduces the&#x000a0;patient's&#x000a0;appetite.<xref ref-type="bibr" rid="article-147813.r9">[9]</xref>&#x000a0;Among patients without diabetes, administering tirzepatide 5 to 15 mg once weekly for managing obesity led to remarkable reductions in body weight, ranging from 16.5% to 22.4% over 72 weeks.&#x000a0;Post hoc analyses of fasting biomarkers indicated that tirzepatide exhibited more significant improvements in markers of insulin sensitivity and &#x003b2;-cell function.<xref ref-type="bibr" rid="article-147813.r10">[10]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Tirzepatide has a bioavailability of approximately 80%. The time it takes to reach peak serum levels can range from 8 to 72 hours.</p>
        <p><bold>Distribution:&#x000a0;</bold>The mean steady-state volume of distribution (Vd) of tirzepatide is approximately 10.3 L. Tirzepatide is highly bound to plasma albumin (99%).</p>
        <p><bold>Metabolism: </bold>When&#x000a0;injected, the peptide structure undergoes proteolytic cleavage. In addition, the C20 fatty diacid composition undergoes &#x003b2;-oxidation and amide hydrolysis.&#x000a0;Being a modified polypeptide, tirzepatide undergoes metabolism into individual amino acids in various tissues, including the liver.<xref ref-type="bibr" rid="article-147813.r6">[6]</xref></p>
        <p><bold>Elimination: </bold>Tirzepatide has a half-life of 5 days,&#x000a0;facilitating weekly dosing, and is cleared in urine and feces as metabolites.<xref ref-type="bibr" rid="article-147813.r11">[11]</xref></p>
      </sec>
      <sec id="article-147813.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Tirzepatide is&#x000a0;administered via the SQ route&#x000a0;and is not yet available in an oral form.</p>
        <p>Tirzepatide&#x000a0;dosages are available in strengths of 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Standard dosing is once weekly; prescribed doses can be increased on follow-up visits based on efficacy, as defined by HbA1c levels, body weight, and adverse effects. The patient's ability to tolerate&#x000a0;adverse effects plays a significant role in dosing titration.&#x000a0;</p>
        <p>The initial dosage of tirzepatide for treatment initiation is 2.5 mg administered SQ once weekly, with the primary goal of initiation rather than glycemic control. After 4 weeks, increase to 5 mg&#x000a0;SQ once weekly. For additional glycemic control, escalate the dosage by 2.5 mg after at least 4 weeks on the current dose. The maximum tirzepatide dosage is 15 mg&#x000a0;SQ once weekly. If a tirzepatide dose is missed, it should be administered within 4 days (96 hours) if feasible; otherwise, skip the missed dose and return to the regular once-weekly schedule.</p>
        <p>
<bold>Specific Patient Population&#x000a0;</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>According to the manufacturer's product information, no dosage adjustment of tirzepatide is suggested for patients with hepatic impairment.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>No dosage adjustment of tirzepatide is suggested for patients with hepatic impairment. However, tirzepatide is associated with gastrointestinal adverse drug reactions, including nausea, vomiting, and diarrhea, leading to dehydration, which&#x000a0;may cause acute kidney injury. Use with caution in patients prone to dehydration.&#x000a0;</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Available information on tirzepatide use in pregnant women is inadequate to evaluate for a drug-related risk of congenital disabilities and adverse maternal or fetal outcomes.&#x000a0;Exposure to the mother and fetus is associated with poorly controlled diabetes in pregnancy. Animal reproduction studies have shown higher occurrences of external, visceral, and skeletal malformations when exposed to tirzepatide. Potential risks exist to the fetus if&#x000a0;ingested during pregnancy. Hence, tirzepatide should only be prescribed to pregnant patients of childbearing age when the benefits outweigh the potential risks and after a thorough discussion of the teratogenic effects.&#x000a0;Clinicians should also&#x000a0;discuss the&#x000a0;decreased efficacy of oral contraceptives and offer non-oral methods for at least 4 weeks after beginning tirzepatide.&#x000a0;</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>No information exists on tirzepatide in animal or human milk or its effects on the breastfed infant. Clinicians should consider the developmental and health benefits of breastfeeding, the mother's need for tirzepatide, and the potential adverse impacts on the breastfed infant. Tirzepatide is a large molecule with high molecular weight. Accordingly, the milk concentration is likely less, and absorption is unlikely because it is presumably partially destroyed in the infant's gastrointestinal tract. Therefore, until more clinical data are available, tirzepatide should be used cautiously during breastfeeding, especially in newborn or preterm infants.<xref ref-type="bibr" rid="article-147813.r12">[12]</xref></p>
        <p><bold>Pediatric patients: </bold>Tirzepatide has not been established as safe and effective for pediatric patients.</p>
        <p><bold>Older patients:</bold> For older patients, in a collective analysis of 7 clinical trials, 30.1% were aged 65 or older, with 4.1% aged 75 or older. While safety and efficacy were comparable to younger counterparts, acknowledging heightened sensitivity in older patients remains crucial.</p>
      </sec>
      <sec id="article-147813.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Based on available data, most users do not experience significant adverse drug reactions. The primary adverse effects are gastrointestinal-related, but other side effects have also been infrequently reported. Decreased appetite is frequently reported, though this is a potential contributory etiology of intentional weight loss. The adverse drug reactions&#x000a0;according to the&#x000a0;System Organ Class (SOC) are listed below.</p>
        <p><bold>Gastrointestinal:</bold> Decreased appetite is often reported. Nausea and diarrhea may occur in up to 10% of patients, in addition to some infrequent reports of vomiting and acid reflux.&#x000a0;Constipation has also been reported in some users.<xref ref-type="bibr" rid="article-147813.r1">[1]</xref>&#x000a0;</p>
        <p><bold>Cardiovascular:</bold> Sinus tachycardia&#x000a0;is reported but may be blunted by concurrent medication use.<xref ref-type="bibr" rid="article-147813.r13">[13]</xref>&#x000a0;</p>
        <p><bold>Renal:</bold> Infrequent cases of acute kidney injury have been reported, likely secondary to dehydration from gastrointestinal losses. These may occur in healthy and preexisting chronic renal disease patients. Monitoring for signs of dehydration is likely to prevent renal injury.</p>
        <p><bold>Dermatologic:</bold> Hypersensitivity reactions have been infrequently reported at the injection site. The prevalence is&#x000a0;similar to those reported by patients using GLP-1 agonists. Such events should be discussed with a&#x000a0;clinician and may warrant medication discontinuation.</p>
        <p><bold>Pancreatitis:</bold> GLP-1 medications are a known risk factor for acute pancreatitis. The risk level for tirzepatide is similar to GLP-1 agonist medications. Patients should be advised to immediately seek care at the local emergency department if they develop severe abdominal pain on tirzepatide therapy. Asymptomatic elevation of lipase and amylase may be seen in some patients.<xref ref-type="bibr" rid="article-147813.r14">[14]</xref></p>
        <p><bold>Hepatobiliary:</bold>&#x000a0;Reports of cholelithiasis and cholecystitis have&#x000a0;occurred in patients on tirzepatide therapy.<xref ref-type="bibr" rid="article-147813.r6">[6]</xref> These adverse effects may be due to the rapid weight loss induced by tirzepatide.<xref ref-type="bibr" rid="article-147813.r6">[6]</xref></p>
        <p><bold>Ocular:</bold> Patients with preexisting diabetic retinopathy should be advised that symptoms may temporarily worsen if glycemic control quickly improves. Any vision changes should be discussed with a clinician.<xref ref-type="bibr" rid="article-147813.r15">[15]</xref></p>
        <p><bold>Endocrine:</bold>&#x000a0;A small risk of hypoglycemia (dose-dependent) exists. This risk is more significant for insulin therapy patients and those utilizing sulfonylureas. Patients&#x000a0;should be advised on the potential symptoms of hypoglycemia.<xref ref-type="bibr" rid="article-147813.r16">[16]</xref></p>
        <p>A recent systematic review, comprising 9 randomized control trials with a total of 9818 patients, indicates that tirzepatide's overall safety&#x000a0;data is similar to that of GLP-1 receptor agonists, except for hypoglycemia at doses higher than 10 mg. Careful attention&#x000a0;is&#x000a0;required&#x000a0;during&#x000a0;adverse events like nausea, vomiting, diarrhea, and injection-site reactions at higher doses.<xref ref-type="bibr" rid="article-147813.r17">[17]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients using other GLP-1 agents, such as semaglutide or liraglutide, should not be prescribed tirzepatide. Patients on insulin therapy can be initiated on tirzepatide therapy and cautiously have the insulin dose decreased to minimize the risk of hypoglycemia.<xref ref-type="bibr" rid="article-147813.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The efficacy of oral hormonal contraceptives&#x000a0;is decreased, so patients should be advised to use non-oral contraceptive methods or&#x000a0;add a barrier contraceptive for&#x000a0;4 weeks after initiation and each dose escalation with tirzepatide.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tirzepatide delays gastric emptying, impacting the absorption of concurrently administered oral medications.&#x000a0;This is particularly significant in those with preexisting delayed gastric emptying, as it can exacerbate&#x000a0;these symptoms. Caution is advised when using oral medications dependent on threshold concentrations or with a narrow therapeutic index (TI) and tirzepatide.<xref ref-type="bibr" rid="article-147813.r19">[19]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-147813.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Tirzepatide is contraindicated in patients with medullary thyroid cancer. Tirzepatide is also contraindicated in multiple endocrine neoplasia syndrome type-2 (MEN-2). For further information, refer to the boxed warning below. Furthermore,&#x000a0;the use is contraindicated in patients with known severe hypersensitivity to tirzepatide or any excipients, as it has been associated with severe hypersensitivity reactions, including anaphylaxis and angioedema.<xref ref-type="bibr" rid="article-147813.r20">[20]</xref>&#x000a0;In patients who have experienced angioedema or anaphylaxis due to GLP-1 receptor agonists, it is important to use tirzepatide cautiously.</p>
        <p>
<bold>Box Warning</bold>
</p>
        <p><bold>Thyroid C-cell tumors:&#x000a0;</bold>Data obtained from animal studies have demonstrated the potential&#x000a0;for developing medullary thyroid carcinoma. It is unknown whether this would also occur in humans. Given the theoretical risk, tirzepatide should be avoided in those with a personal or family history of medullary thyroid carcinoma. Patients with a history of MEN-2 should also avoid tirzepatide. Patients with other thyroid cancer-related risk factors should be advised of the theoretical risks. Routine serum calcitonin or thyroid ultrasound monitoring is inconclusive for early detection of medullary thyroid cancer.<xref ref-type="bibr" rid="article-147813.r21">[21]</xref><xref ref-type="bibr" rid="article-147813.r22">[22]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Relative contraindications also exist, such as gallbladder disease or diabetic retinopathy.<xref ref-type="bibr" rid="article-147813.r6">[6]</xref>&#x000a0;Tirzepatide is only approved for those with&#x000a0;T2DM and should not be used for those with T1DM.&#x000a0;Furthermore, tirzepatide does not have approval for other forms of diabetes, like latent autoimmune diabetes in adults.<xref ref-type="bibr" rid="article-147813.r23">[23]</xref><xref ref-type="bibr" rid="article-147813.r24">[24]</xref></p>
      </sec>
      <sec id="article-147813.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients should have HbA1c and body weight monitored during follow-up visits. Follow-up intervals vary depending on the local standard of care for diabetes management and obesity treatment. HbA1c monitoring is usually implemented every&#x000a0;3 months, depending on the patient and&#x000a0;the A1c goal.<xref ref-type="bibr" rid="article-147813.r25">[25]</xref>&#x000a0;Continuous glucose monitoring can also be used to assess response.<xref ref-type="bibr" rid="article-147813.r26">[26]</xref></p>
        <p>Hemolytic anemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and pregnancy can lead to discrepancies between the A1c result and the patient's true glycemic status. Given the significantly improved insulin sensitivity on tirzepatide, patients who use insulin should be instructed to monitor blood sugars more closely.<xref ref-type="bibr" rid="article-147813.r10">[10]</xref><xref ref-type="bibr" rid="article-147813.r27">[27]</xref></p>
        <p>Hemolytic anemia, G6PD deficiency, and pregnancy can lead to discrepancies between the A1c result and the patient's actual glycemic status.</p>
        <p>Monitoring for side effects, such as gastrointestinal-related symptoms, may be necessary, especially as the prescribed doses increase. In addition, the asymptomatic elevation of lipase and amylase levels can be seen in patients using tirzepatide. Still, clinical data do not suggest utility in monitoring these markers without symptoms.&#x000a0;</p>
        <p>The efficacy of routine monitoring of serum calcitonin or thyroid ultrasound for early detection of medullary carcinoma of the thyroid in patients undergoing tirzepatide treatment&#x000a0;is uncertain. In addition, such monitoring may increase the risk of unnecessary procedures. However,&#x000a0;if thyroid nodules are monitored on physical examination, and if serum calcitonin &#x0003e;50 ng/L, then further diagnostic assessment of the patient for medullary carcinoma of the thyroid is required.<xref ref-type="bibr" rid="article-147813.r16">[16]</xref></p>
        <p>Integration of quality of life (QOL) assessment into routine care provides the optimum clinical care for patients with T2DM. Monitoring of Diabetes-Dependent Quality of Life (ADDQoL), Diabetes Quality of Life (DQoL), and Short Form-12 (SF-12) help monitor the QOL in patients with T2DM.<xref ref-type="bibr" rid="article-147813.r28">[28]</xref></p>
      </sec>
      <sec id="article-147813.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Patients who overdose on tirzepatide should be monitored for any changes in clinical status. As this medication has a long half-life, patients may require prolonged monitoring. Clinicians should contact poison control; consultation with a toxicologist may be necessary.&#x000a0;No current antidote for tirzepatide overdose exists, and supportive care is most beneficial.</p>
        <p>Patients with acute pancreatitis present with abdominal pain, serum lipase &#x0003e;3 ULN, and evidence of acute pancreatitis on imaging. American Gastroenterological Association guidelines&#x000a0;recommend goal-directed fluid management for patients with acute pancreatitis.<xref ref-type="bibr" rid="article-147813.r29">[29]</xref> Extended monitoring of patients might be warranted following an overdose, given the half-life of tirzepatide, which is approximately&#x000a0;5 days.<xref ref-type="bibr" rid="article-147813.r24">[24]</xref></p>
      </sec>
      <sec id="article-147813.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Tirzepatide is a novel medication approved for treating&#x000a0;T2DM&#x000a0;with the added benefit of weight loss. Clinicians are likely to prescribe it in uncontrolled diabetes after first-line therapy. Current clinical data have shown that tirzepatide&#x000a0;is highly efficacious in improving HbA1c levels and reducing body weight.<xref ref-type="bibr" rid="article-147813.r3">[3]</xref></p>
        <p>According to the ADA guidelines, an HbA1c goal of &#x0003c;7% is appropriate for many nonpregnant adults.<xref ref-type="bibr" rid="article-147813.r30">[30]</xref>&#x000a0;According to guidelines, if the HbA1c target is not achieved after&#x000a0;3 months of metformin monotherapy, metformin can be combined with a GLP-1 receptor agonist (preferred in patients with a compelling need for weight loss) or other agents based on comorbidities and shared decision-making.<xref ref-type="bibr" rid="article-147813.r31">[31]</xref></p>
        <p>After initiating therapy with tirzepatide, clinicians are likely to follow up with patients in set intervals as early as&#x000a0;4 weeks or as late as 12 weeks, depending on the dosage and the local standard of care for diabetes management. Pharmacists support patients using tirzepatide by carrying out specific responsibilities, including dispensing the medication, counseling patients on potential adverse effects, and occasionally monitoring their HbA1c levels.</p>
        <p>Specific care teams incorporate pharmacists into diabetes management. Nurses are the anticipated initial point of contact for discussing tirzepatide's adverse effects. Clinicians should also educate patients about warning symptoms of hypoglycemia, such as irritability, tremors, and confusion.</p>
        <p>Tirzepatide is also likely prescribed in weight loss clinics, similar to GLP-1 medications. Obesity management clinics often incorporate multidisciplinary care that includes dietitians or social workers to help maximize patient outcomes. Given the popularity of semaglutide in weight loss clinics, tirzepatide will likely gain similar popularity among&#x000a0;clinicians and patients, given the high levels of reported efficacy. However, the clinical data have shown that weight reduction appears to be dose-dependent; weight loss management may be limited by the ability of the patient to tolerate higher doses of tirzepatide.</p>
        <p>A recent systematic review and meta-analysis found that interprofessional collaboration among specialists, clinicians, nurses, and other healthcare providers notably enhances patient-reported outcomes in individuals with T2DM.<xref ref-type="bibr" rid="article-147813.r32">[32]</xref> Meticulous record-keeping in the patient's medical record is crucial to ensure all team members can access updated and accurate patient data for decision-making.</p>
      </sec>
      <sec id="article-147813.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=147813&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=147813">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/147813/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=147813">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-147813.s11">
        <title>References</title>
        <ref id="article-147813.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <article-title>Tirzepatide (Mounjaro) for type 2 diabetes.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2022</year>
            <month>Jul</month>
            <day>11</day>
            <volume>64</volume>
            <issue>1654</issue>
            <fpage>105</fpage>
            <page-range>105-107</page-range>
            <pub-id pub-id-type="pmid">35802842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Collins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <chapter-title>Glucagon-Like Peptide-1 Receptor Agonists</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">31855395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Onishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Norwood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>&#x000c1;</given-names>
              </name>
            </person-group>
            <article-title>Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Feb</month>
            <day>08</day>
            <volume>327</volume>
            <issue>6</issue>
            <fpage>534</fpage>
            <page-range>534-545</page-range>
            <pub-id pub-id-type="pmid">35133415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.</article-title>
            <source>Nat Med</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>1500</fpage>
            <page-range>1500-1510</page-range>
            <pub-id pub-id-type="pmid">37231074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maruthur</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Del Prato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mathieu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mingrone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tankova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsapas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).</article-title>
            <source>Diabetes Care</source>
            <year>2022</year>
            <month>Nov</month>
            <day>01</day>
            <volume>45</volume>
            <issue>11</issue>
            <fpage>2753</fpage>
            <page-range>2753-2786</page-range>
            <pub-id pub-id-type="pmid">36148880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <chapter-title>Tirzepatide</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">35780672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valenzuela-Vallejo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guatibonza-Garc&#x000ed;a</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mantzoros</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?</article-title>
            <source>Metabolism</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>136</volume>
            <fpage>155248</fpage>
            <pub-id pub-id-type="pmid">35803320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Surana</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Singla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>475</fpage>
            <page-range>475-489</page-range>
            <pub-id pub-id-type="pmid">35355921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Willard</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alsina-Fernandez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Vieth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Showalter</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Stutsman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Suter</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Dunbar</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Aihara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Emmerson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Moyers</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kobilka</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Coghlan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kobilka</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Sloop</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Structural determinants of dual incretin receptor agonism by tirzepatide.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2022</year>
            <month>Mar</month>
            <day>29</day>
            <volume>119</volume>
            <issue>13</issue>
            <fpage>e2116506119</fpage>
            <pub-id pub-id-type="pmid">35333651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Nikooienejad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Duffin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Milicevic</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Haupt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robins</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2021</year>
            <month>Jan</month>
            <day>23</day>
            <volume>106</volume>
            <issue>2</issue>
            <fpage>388</fpage>
            <page-range>388-396</page-range>
            <pub-id pub-id-type="pmid">33236115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bucheit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ayers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pamulapati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Browning</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sisson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>2022</year>
            <month>Aug</month>
            <day>01</day>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-179</page-range>
            <pub-id pub-id-type="pmid">35767712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Tirzepatide</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">35759552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farzam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Beta Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">30422501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trujillo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>45 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>43</fpage>
            <page-range>43-60</page-range>
            <pub-id pub-id-type="pmid">32910487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bethel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Castellana</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhattacharya</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gerstein</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lakshmanan</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>HbA<sub>1c</sub> Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression.</article-title>
            <source>Diabetes Care</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>290</fpage>
            <page-range>290-296</page-range>
            <pub-id pub-id-type="pmid">33444163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chavda</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Ajabiya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Teli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bojarska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Apostolopoulos</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.</article-title>
            <source>Molecules</source>
            <year>2022</year>
            <month>Jul</month>
            <day>05</day>
            <volume>27</volume>
            <issue>13</issue>
            <pub-id pub-id-type="pmid">35807558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1121387</fpage>
            <pub-id pub-id-type="pmid">37051199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kroopnick</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1259</fpage>
            <page-range>1259-1271</page-range>
            <pub-id pub-id-type="pmid">35765193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krauss</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hintz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fisk</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Tirzepatide: Clinical review of the "twincretin" injectable.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2023</year>
            <month>Jul</month>
            <day>07</day>
            <volume>80</volume>
            <issue>14</issue>
            <fpage>879</fpage>
            <page-range>879-888</page-range>
            <pub-id pub-id-type="pmid">37070418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <chapter-title>Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2022</year>
            <month>8</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">25905364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallwitz</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>1004044</fpage>
            <pub-id pub-id-type="pmid">36313764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samuel</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Varghese</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kubatka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>B&#x000fc;sselberg</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Tirzepatide-Friend or Foe in Diabetic Cancer Patients?</article-title>
            <source>Biomolecules</source>
            <year>2022</year>
            <month>Oct</month>
            <day>28</day>
            <volume>12</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">36358930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fr&#x000ed;as</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez Manghi</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez Land&#x000f3;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>K</given-names>
              </name>
              <collab>SURPASS-2 Investigators</collab>
            </person-group>
            <article-title>Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Aug</month>
            <day>05</day>
            <volume>385</volume>
            <issue>6</issue>
            <fpage>503</fpage>
            <page-range>503-515</page-range>
            <pub-id pub-id-type="pmid">34170647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Min</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type&#x000a0;2 Diabetes: The SURPASS Clinical Trials.</article-title>
            <source>Diabetes Ther</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-157</page-range>
            <pub-id pub-id-type="pmid">33325008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sapra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhandari</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Diabetes</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">31855345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Battelino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bergenstal</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez Land&#x000f3;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>407</fpage>
            <page-range>407-417</page-range>
            <pub-id pub-id-type="pmid">35468321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pirro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Willency</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Milligan</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ruotolo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haupt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Newgard</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Duffin</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2022</year>
            <month>Jan</month>
            <day>18</day>
            <volume>107</volume>
            <issue>2</issue>
            <fpage>363</fpage>
            <page-range>363-378</page-range>
            <pub-id pub-id-type="pmid">34608929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kachan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Outcome tools for diabetes-specific quality of life: Study performed in a private family practice clinic.</article-title>
            <source>Can Fam Physician</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>6</issue>
            <fpage>e310</fpage>
            <page-range>e310-e315</page-range>
            <pub-id pub-id-type="pmid">28615409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crockett</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Falck-Ytter</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Barkun</surname>
                <given-names>AN</given-names>
              </name>
              <collab>American Gastroenterological Association Institute Clinical Guidelines Committee</collab>
            </person-group>
            <article-title>American Gastroenterological Association Institute Guideline on&#x000a0;Initial Management of Acute Pancreatitis.</article-title>
            <source>Gastroenterology</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>154</volume>
            <issue>4</issue>
            <fpage>1096</fpage>
            <page-range>1096-1101</page-range>
            <pub-id pub-id-type="pmid">29409760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>6. Glycemic Targets: <italic>Standards of Medical Care in Diabetes-2021</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>Suppl 1</issue>
            <fpage>S73</fpage>
            <page-range>S73-S84</page-range>
            <pub-id pub-id-type="pmid">33298417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>9. Pharmacologic Approaches to Glycemic Treatment: <italic>Standards of Medical Care in Diabetes-2021</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>Suppl 1</issue>
            <fpage>S111</fpage>
            <page-range>S111-S124</page-range>
            <pub-id pub-id-type="pmid">33298420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147813.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nurchis</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sessa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pascucci</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sassano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lombi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Damiani</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional Collaboration and Diabetes Management in Primary Care: A Systematic Review and Meta-Analysis of Patient-Reported Outcomes.</article-title>
            <source>J Pers Med</source>
            <year>2022</year>
            <month>Apr</month>
            <day>15</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35455759</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
